2014

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0787705/Chemotherapy-Induced-Nausea-and-Vomiting-CINV-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report identifies the key trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chemotherapy induced Nausea and Vomiting Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Chemotherapy induced Nausea and Vomiting Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chemotherapy induced Nausea and Vomiting Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Chemotherapy induced Nausea and Vomiting Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chemotherapy induced Nausea and Vomiting Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Chemotherapy induced Nausea and Vomiting Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chemotherapy induced Nausea and Vomiting Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Chemotherapy induced Nausea and Vomiting Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Introduction 7

2.1 Overview 7

2.1.1 Classification of Chemotherapy-Induced Nausea and Vomiting 7

2.2 Risk factors for Chemotherapy-Induced Nausea and Vomiting 8

2.3 Epidemiology 10

2.4 Symptoms 10

2.5 Etiology 10

2.6 Pathophysiology 11

2.7 Diagnosis 13

2.8 Treatment of Chemotherapy-Induced Nausea and Vomiting 13

2.8.1 Current Guidelines 13

2.8.2 Prevention of CINV by Emetogenic Potential of Chemotherapy and Class 20

2.9 GlobalData Pipeline Report Guidance 22

3 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Market Characterization 23

3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Global 23

3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Global 25

3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the US 27

3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the US 28

3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - France 29

3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - France 30

3.7 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Germany 31

3.8 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Germany 32

3.9 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Italy 33

3.10 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Italy 34

3.11 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Spain 35

3.12 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Spain 36

3.13 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the UK 37

3.14 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the UK 38

3.15 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Japan 39

3.16 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Japan 40

3.17 Drivers and Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41

3.17.1 Drivers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41

3.17.2 Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41

3.18 Key Events Impacting the Future Market 42

3.19 Opportunity and Unmet Need Analysis 42

3.19.1 Key Takeaway 43

4 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Competitive Assessment 44

4.1 Overview 44

4.2 Strategic Competitor Assessment 44

4.3 Product Profile for the Major Marketed Products in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 45

4.3.1 Anzemet (dolasetron mesylate) 45

4.3.2 Kytril (granisetron) 46

4.3.3 Sancuso (granisetron Transdermal System) 47

4.3.4 Zuplenz/Zofran (ondansetron) 48

4.3.5 Aloxi (palonosetron hydrochloride) 49

4.3.6 Emend (aprepitant/fosaprepitant dimeglumine) 50

4.4 Key Takeaway 52

5 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment 53

5.1 Overview 53

5.2 Strategic Pipeline Assessment 53

5.3 Chemotherapy-Induced Nausea and Vomiting Pipeline - Pipeline by Phases of Development 53

5.3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pre-registration Pipeline 54

5.3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase III Pipeline 54

5.3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase II Pipeline 54

5.3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase I Pipeline 54

5.3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Preclinical 55

5.3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Discovery 55

5.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Mechanism of Action 55

5.5 Chemotherapy-Induced Nausea and Vomiting Technology Trends Analytical Framework 56

5.6 Molecule Profile for Key Late Stage Drugs under Clinical Development 57

5.6.1 APF530 57

5.6.2 EUR-1025 58

5.6.3 Netupitant 58

5.7 Key takeaway 58

6 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Clinical Trials Mapping 59

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 59

6.2 Clinical Trials Mapping by Phase 60

6.3 Clinical Trials Mapping by Trial Status 61

6.4 Overall Sponsors 62

6.5 Prominent Sponsors 63

6.6 Top Companies Participating in Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trials 64

7 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Strategic Assessment 65

7.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Implications for Future Market Competition 65

8 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Future Players 66

8.1 Introduction 66

8.2 Company Profiles 66

8.2.1 A.P. Pharma Inc. 66

8.2.2 Aptalis Pharma, Inc. 68

8.2.3 Eisai Co. Ltd 69

8.2.4 Helsinn Healthcare S.A. 71

9 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Licensing and Partnership Deals 72

10 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Appendix 74

10.1 Definitions 74

10.2 Acronyms 74

10.3 Research Methodology 75

10.3.1 Coverage 75

10.3.2 Secondary Research 76

10.3.3 Forecasting 76

10.3.4 Primary Research 78

10.3.5 Expert Panel Validation 79

10.4 Contact Us 79

10.5 Disclaimer 79

10.6 Bibliography 79

 

1.1 List of Tables

 

 

Table 1: Chemotherapy Induced Nausea and Vomiting, Emetic Risk Levels of Major Chemotherapeutic Agents 9

Table 2: Chemotherapy-Induced Nausea and Vomiting, Marketed Drugs 16

Table 3: CINV Therapeutics Market, Global, Forecast ($m), 2006 - 2011 24

Table 4: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Forecast ($bn), 2011 - 2019 25

Table 5: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Revenue ($m), 2006 - 2011 27

Table 6: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Forecast ($m), 2011 - 2019 28

Table 7: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Revenue ($m), 2006 - 2011 29

Table 8: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Forecast ($m), 2011 - 2019 30

Table 9: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 31

Table 10: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 32

Table 11: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 33

Table 12: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 34

Table 13: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 35

Table 14: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 36

Table 15: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 37

Table 16: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 38

Table 17: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 39

Table 18: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 40

Table 19: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pre-registration Pipeline, 2011 54

Table 20: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase III Pipeline, 2011 54

Table 21: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase II Pipeline, 2011 54

Table 22: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase I Pipeline, 2011 54

Table 23: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Preclinical Pipeline, 2011 55

Table 24: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Discovery Pipeline, 2011 55

Table 25: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Country, 2011 59

Table 26: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Phase, 2011 60

Table 27: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Status, 2011 61

Table 28: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Overall Sponsors, 2011 62

Table 29: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Prominent Sponsors, 2011 63

Table 30: Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 64

Table 31: A.P. Pharma - Chemotherapy-Induced Nausea and Vomiting Pipeline 67

Table 32: Aptalis Pharma - Chemotherapy-Induced Nausea and Vomiting Pipeline 69

Table 33: Eisai Co. Ltd - Chemotherapy-Induced Nausea and Vomiting Pipeline 70

Table 34: Helsinn Healthcare S.A. - Chemotherapy-Induced Nausea and Vomiting Pipeline 71

Table 35: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Global, Deals 72

 

List of Figures

 

 

Figure 1: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011 7

Figure 2: Chemotherapy-Induced Nausea and Vomiting Risk Factors 8

Figure 3: Systems involved in Pathophysiology of Chemotherapy-Induced Nausea and Vomiting 11

Figure 4: Pathophysiology of Chemotherapy-Induced Nausea and Vomiting 12

Figure 5: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Alignment of Recommendations 14

Figure 6: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Revenue ($bn), 2006 - 2011 23

Figure 7: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Market Share ($m, %), 2011 24

Figure 8: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Global, Forecast ($bn), 2011 - 2019 25

Figure 9: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Market Share ($m, %), 2019 26

Figure 10: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Revenue ($m), 2006 - 2011 27

Figure 11: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the US, Forecast ($m), 2011 - 2019 28

Figure 12: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Revenue ($m), 2006 - 2011 29

Figure 13: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, France, Forecast ($m), 2011 - 2019 30

Figure 14: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 31

Figure 15: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 32

Figure 16: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 33

Figure 17: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 34

Figure 18: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 35

Figure 19: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 36

Figure 20: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 37

Figure 21: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 38

Figure 22: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 39

Figure 23: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 40

Figure 24: Chemotherapy-Induced Nausea and Vomiting Therapeutics Market, Drivers and Barriers, 2011 42

Figure 25: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Opportunity and Unmet Need, 2011 43

Figure 26: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Strategic Competitor Assessment, 2011 45

Figure 27: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Phase of Clinical Development, 2011 53

Figure 28: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Pipeline by Mechanism Of Action, 2011 55

Figure 29: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Technology Trends Analytical Framework, , 2011 56

Figure 30: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Technology Trends Analytical Framework, Description, 2011 57

Figure 31: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Country, 2011 59

Figure 32: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Phase, 2011 60

Figure 33: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical Trials by Status, 2011 61

Figure 34: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Overall Sponsors, 2011 62

Figure 35: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Clinical trials by Prominent Sponsors, 2011 63

Figure 36: Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 64

Figure 37: Chemotherapy-Induced Nausea and Vomiting Therapeutics, Strategic Assessment, 2011 65

Figure 38: Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Company, 2011 66

Companies mentioned

A.P. Pharma Inc.

Aptalis Pharma, Inc.

Eisai Co. Ltd

Helsinn Healthcare S.A.

To order this report:

: Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

__________________________

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.